Bédard A, Basagaña X, Anto J M, Garcia-Aymerich J, Devillier P, Arnavielhe S, Bedbrook A, Onorato G L, Czarlewski W, Murray R, Almeida R, Fonseca J A, Correia da Sousa J, Costa E, Morais-Almeida M, Todo-Bom A, Cecchi L, De Feo G, Illario M, Menditto E, Monti R, Stellato C, Ventura M T, Annesi-Maesano I, Bosse I, Fontaine J F, Pham-Thi N, Thibaudon M, Schmid-Grendelmeier P, Spertini F, Chavannes N H, Fokkens W J, Reitsma S, Dubakiene R, Emuzyte R, Kvedariene V, Valiulis A, Kuna P, Samolinski B, Klimek L, Mösges R, Pfaar O, Shamai S, Roller-Wirnsberger R E, Tomazic P V, Ryan D, Sheikh A, Haahtela T, Toppila-Salmi S, Valovirta E, Cardona V, Mullol J, Valero A, Makris M, Papadopoulos N G, Prokopakis E P, Psarros F, Bachert C, Hellings P W, Pugin B, Bindslev-Jensen C, Eller E, Kull I, Melén E, Wickman M, De Vries G, van Eerd M, Agache I, Ansotegui I J, Bosnic-Anticevich S, Cruz A A, Casale T, Ivancevich J C, Larenas-Linnemann D E, Sofiev M, Wallace D, Waserman S, Yorgancioglu A, Laune D, Bousquet J
ISGlobal, Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Clin Transl Allergy. 2020 Dec 9;10(1):62. doi: 10.1186/s13601-020-00342-x.
The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information including the phenotypic characteristics of the users.
The Allergy Diary-MASK-air-mobile phone app, freely available via Google Play and App, was used to collect the data of daily visual analogue scales (VASs) for overall allergic symptoms and medication use. Fluticasone Furoate (FF), Mometasone Furoate (MF), Azelastine Fluticasone Proprionate combination (MPAzeFlu) and eight oral H1-antihistamines were studied. Phenotypic characteristics were recorded at entry. The ARIA severity score was derived from entry data. This was an a priori planned analysis.
9037 users filled in 70,286 days of VAS in 2016, 2017 and 2018. The ARIA severity score was lower outside than during the pollen season. Severity was similar for all treatment groups during the pollen season, and lower in the MPAzeFlu group outside the pollen season. Days with MPAzeFlu had lower VAS levels and a higher frequency of monotherapy than the other treatments during the season. Outside the season, days with MPAzeFlu also had a higher frequency of monotherapy. The number of reported days was significantly higher with MPAzeFlu during and outside the season than with MF, FF or oral H1-antihistamines.
This study shows that the overall efficacy of treatments is similar during and outside the pollen season and indicates that medications are similarly effective during the year.
移动健康（mHealth）数据的分析为改善过敏性鼻炎的控制带来了创新性见解，但仍需要更多补充信息。在17个欧洲国家的预计花粉季节期间及之外开展了一项横断面真实世界观察性研究。目的是收集包括用户表型特征在内的新信息。
通过谷歌Play和App免费获取的“过敏日记-MASK-空气-手机”应用程序，用于收集每日视觉模拟量表（VAS）中关于总体过敏症状和药物使用的数据。对糠酸氟替卡松（FF）、糠酸莫米松（MF）、氮卓斯汀氟替卡松丙酸酯组合（MPAzeFlu）和8种口服H1抗组胺药进行了研究。在入组时记录表型特征。ARIA严重程度评分来自入组数据。这是一项预先计划的分析。
9037名用户在2016年、2017年和2018年填写了70286天的VAS。ARIA严重程度评分在花粉季节之外低于花粉季节期间。在花粉季节期间，所有治疗组的严重程度相似，而在花粉季节之外，MPAzeFlu组的严重程度较低。在花粉季节期间，使用MPAzeFlu的日子VAS水平较低，且单药治疗的频率高于其他治疗。在花粉季节之外，使用MPAzeFlu的日子单药治疗的频率也较高。在花粉季节期间及之外，报告使用MPAzeFlu的天数显著高于使用MF、FF或口服H1抗组胺药的天数。
本研究表明，在花粉季节期间及之外，治疗的总体疗效相似，表明这些药物在一年中效果相似。
